Is R-CHOP Therapy a Lymphoma Growth Factor?
Laure Farnault(Aix-Marseille Université), Régis Costello(Inserm), G Sébahoun(Hôpital de la Conception), Yaël Berda‐Haddad(Assistance Publique Hôpitaux de Marseille), Cédric Mercier(Inserm)
Cited by 1
Related Papers
Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio‐Oncology Guidelines
|Journal of the American Heart Association|2020|298
ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition
|Blood|2021|157
Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors
|Blood Cancer Journal|2016|74
High incidence of atrial fibrillation in patients treated with ibrutinib
|Open Heart|2019|72
Hematological Malignancies Escape from NK Cell Innate Immune Surveillance: Mechanisms and Therapeutic Implications
|Clinical and Developmental Immunology|2012|60